Journal Logo

Video Gallery

Drs. Ryan Fields & Todd Fehniger Discuss Natural Killer Cells for the Treatment of Melanoma


Published on: 08.24.2021

An immunotherapy treatment approach using the immune system’s natural killer cells has been effective in treating patients with recurrent leukemia and other difficult to treat blood cancers. Now, researchers at Washington University Siteman Cancer Center in St. Louis have shown in preclinical studies conducted in mice and human cells that this type of cell-based immunotherapy also could be effective against solid tumors, starting with melanoma. Ryan Fields, MD, a surgeon specializing in a surgical oncology and Todd Fehniger, MD, PhD, Bone Marrow Transplant Specialist, and Medical Oncologist discuss their recent findings and the transformation of cancer care at Siteman Cancer Center.

All Videos
Most Viewed
Most Emailed



Creator:
Duration: 9:23
An immunotherapy treatment approach using the immune system’s natural killer cells has been effective in treating patients with recurrent leukemia and other difficult to treat blood cancers. Now, researchers at Washington University Siteman Cancer Center in St. Louis have shown in preclinical studies conducted in mice and human cells that this type of cell-based immunotherapy also could be effective against solid tumors, starting with melanoma. Ryan Fields, MD, a surgeon specializing in a surgical oncology and Todd Fehniger, MD, PhD, Bone Marrow Transplant Specialist, and Medical Oncologist discuss their recent findings and the transformation of cancer care at Siteman Cancer Center.
Play Video |
Creator: Peter M. Goodwin
Duration: 0:32
INDIANAPOLIS, Indiana—A non-randomized 36-patient phase-two clinical study found a big reduction in acute graft-versus-host disease (GVHD) after adding the dipeptidyl peptidase-4 (DPP-4, also known as CD26) inhibitor sitagliptin (long established as an anti-glycemic agent for treating type-2 diabetes) to immunosuppression therapy for allogeneic stem-cell transplantation.

“Impressively we found a very low rate of grade two to four acute graft versus host disease. Of the 36 patients we had only two patients who developed acute graft versus host disease by day 100. One had grade two, one had grade four,” said Sherif S. Farag MD PHD, Director of the Stem Cell Transplant and Cellular Therapy Program at Indiana University School of Medicine’s Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, after publication of his group’s report in the New England Journal of Medicine (nejm.org/doi/full/10.1056/NEJMoa2027372).
Play Video |
Creator:
Duration: 1:22
A new study has detailed how South Korea's carefully prepared and pre-planned combination of pandemic mitigation measures successfully curtailed the country's biggest outbreak of COVID-19 early in 2020, without resorting to formal lockdown. Oncology Times reporter Peter M. Goodwin sits down with Harvard University's June-Ho Kim, MD, MPH, from Ariadne Laboratories at Brigham and Women's Hospital, and lead author of the study reported in the journal NEJM Catalyst to discuss the findings.
Play Video |
Creator: Oncology Times
Duration: 2:43
Pierluigi Porcu, MD, Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at the Sidney Kimmel Cancer Center at Jefferson Health, discusses a few hematology/oncology clinical trials in which he and his team are involved.
Play Video |
Creator: Convention News Television
Duration: 3:20
Oncologists across disciplines share their passion for the profession and discuss why they chose a career in cancer care.
Play Video |
Creator: Convention News Television
Duration: 1:08
Dean H. Gesme, MD, FASCO, FACP, MD, from Minnesota Oncology, shares his passion for cancer care and the rewards of oncology practice.
Play Video |
Creator: Convention News Television
Duration: 0:46
A. Craig Lockhart, MD, from Sylvester Comprehensive Cancer Center, became an oncologist to improve the standard-of-care and make a difference in the lives of cancer patients.
Play Video |
Creator: Convention News Television
Duration: 1:28
Ramaswamy Govindan, MD, from the Washington University School of Medicine, St. Louis, Mo., discusses the breakthroughs he has witnessed in cancer research and treatment as well as why this is an exciting time to be an oncologist.
Play Video |
Creator: Convention News Television
Duration: 1:02
Paul Bunn, MD, FASCO, of the University of Colorado Cancer Center, discusses why he became an oncologist as well as his passion for research and patient care.
Play Video |
Creator: Convention News Television
Duration: 0:43
Find out why Stephen D. Nimer, MD, of Sylvester Comprehensive Cancer Center, chose to pursue a career in oncology.
Play Video |
Creator: Convention News Television
Duration: 1:20
Ishwaria M. Subbiah, MD, MS, of the University of Texas MD Anderson Cancer Center, Houston, shares her passion for oncology and quality patient care.
Play Video |
Creator: Sarah Maxwell
Duration: 4:22
Icro Meattini, MD, Consultant Clinical Oncologist at the University of Florence, discusses a subgroup analysis of a Phase III randomized study of women with early breast cancer, which he presented at the 2015 European Society for Radiotherapy & Oncology Forum in Barcelona.
Play Video |
Creator: Dan Keller
Duration: 5:41
Patrick Hwu, MD, Chair of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses topics from a session on immunotherapy of melanoma at the International Meeting of the Society for Melanoma Research, and he summarizes presentations on the need for biomarkers for patient selection and as potential therapeutic targets themselves, the utility of immunotherapy plus radiation, and stimulation of antigen-presenting cells.
Play Video |
Creator: Sarah Maxwell
Duration: 1:44
Professor Hans Wildiers, MD, PhD, from the University Hospitals Multidisciplinary Breast Centre in Leuven, Belgium, explains why TDM-1 doubles progression-free survival in HER2-positive advanced refractory breast cancer.
Play Video |
Creator: Dan Keller
Duration: 5:39
Richard Furman, MD, discusses the Phase III trial of idelalisib, a first-in-class oral kinase inhibitor and highly selective inhibitor of the delta isoform of PI3 kinase, used in combination with rituximab. The data show better progression-free survival and objective response rates compared with rituximab plus placebo in CLL patients who had already received standard treatments and were not considered candidates for additional chemotherapy.
Play Video |
Creator: Dan Keller
Duration: 5:29
Smita Bhatia, MD, MPH, elaborates on the clinical implications of her research.
Play Video |
Creator: Peter Goodwin
Duration: 1:50
Changes in colorectal cancer mortality are found to be correlated with the level of screening uptake—providing a strong rationale for national bowel cancer screening programs, this researcher explains.
Play Video |
Creator: Dan Keller
Duration: 5:20
Jedd Wolchok, MD, elaborates on his presentation at the 10th International Meeting of the Society for Melanoma Research about the need for therapies for melanoma beyond current CTLA-4 blockade, findings on biomarkers for response, PD-L1 expression as a biomarker on tumor cells, and the potential for targeted combination treatments.
Play Video |
Creator: Peter Goodwin
Duration: 2:10
TARGIT-A investigators Jayant S. Vaidya, PhD, and Michael Baum, MB, ChB, FRCS, elaborate on their findings and the clinical implications.
Play Video |
Creator: Dan Keller
Duration: 6:51
Valentin Goede, MD, elaborates on the clinical implications of the “paradigm-changing” CLL11 Phase III study that found improved responses for patients with chronic lymphocytic leukemia receiving obinutuzumab-chlorambucil compared with those receiving rituximab-chlorambucil.
Play Video |



Creator: Dan Keller
Duration: 5:20
Jedd Wolchok, MD, elaborates on his presentation at the 10th International Meeting of the Society for Melanoma Research about the need for therapies for melanoma beyond current CTLA-4 blockade, findings on biomarkers for response, PD-L1 expression as a biomarker on tumor cells, and the potential for targeted combination treatments.
Play Video |